Evidence map›Paper›PMID 37692864›Full record

ArticleJournal of hematology2023

Leukostasis With Isolated Central Nervous System Involvement in Chronic Phase of Chronic Myelogenous Leukemia.

Won Jin Jeon, Suhani Dalal, Jin Hyun Moon, Bowon Joung, Michael Nguyen, Dani Castillo, Jessica Hudson, Kiwon Park, Ravi Raghavan, Mojtaba Akhtari and 1 more

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Won Jin JeonDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA.ORCID https://orcid.org/0000-0001-5212-5284
Suhani DalalDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Jin Hyun MoonDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Bowon JoungDepartment of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA, USA.
Michael NguyenDivision of Medical Oncology/Hematology, Department of Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA.
Dani CastilloDivision of Medical Oncology, City of Hope, Duarte, CA, USA.
Jessica HudsonDivision of Anatomic and Surgical Pathology, Loma Linda University Medical Center, Loma Linda, CA, USA.
Kiwon ParkDepartment of Pharmacy, Loma Linda University, Loma Linda, CA, USA.
Ravi RaghavanDivision of Anatomic and Surgical Pathology, Loma Linda University Medical Center, Loma Linda, CA, USA.
Mojtaba AkhtariDivision of Medical Oncology/Hematology, Department of Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA.
Ami PatelDivision of Medical Oncology/Hematology, Department of Internal Medicine, Loma Linda University Medical Center, Loma Linda, CA, USA.
Loma Linda University · USLoma Linda University Medical Center · USCity Of Hope National Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic myelogenous leukemia (CML) is a hematologic malignancy with unique significance to the field of hematology and oncology, specifically due to the development of tyrosine kinase inhibitors (TKIs). CML often presents with nonspecific symptoms, and the quality of life in patients with CML has drastically improved as a result of TKIs. However, complications of CML including the risk of transforming into life-threatening blast crises continue to exist. Further, as most patients are asymptomatic in the chronic phase, patients often present with serious complications associated with noncompliance to TKIs. For example, central nervous system (CNS) manifestations of CML have been reported, both as the initial presentation of undiagnosed CML and as known complication of uncontrolled CML. Hyperleukocytosis is a manifestation of uncontrolled CML and leukostasis is a complication, occurring in cases of acute myeloid leukemia (AML). Here we present a rare case of leukostasis in a patient with known CML presenting on computed tomography (CT) as intracranial masses in the chronic phase. Our goal is to discuss this rare case of leukostasis in adult CML and describe its management.

Indexed as

Central nervous systemChronic myelogenous leukemiaHyperleukocytosisLeukostasis

Identifiers

PMID37692864
PMCPMC10482607
OpenAlexW4386280296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.